CN116490199A - 用于治疗患有冠状病毒感染的受试者的trem-1抑制剂 - Google Patents

用于治疗患有冠状病毒感染的受试者的trem-1抑制剂 Download PDF

Info

Publication number
CN116490199A
CN116490199A CN202180057069.6A CN202180057069A CN116490199A CN 116490199 A CN116490199 A CN 116490199A CN 202180057069 A CN202180057069 A CN 202180057069A CN 116490199 A CN116490199 A CN 116490199A
Authority
CN
China
Prior art keywords
trem
seq
level
strem
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180057069.6A
Other languages
English (en)
Chinese (zh)
Inventor
马尔克·德里夫
M·萨尔塞多-马吉利
J-J·加罗
S·兰姆登
A·奥利维尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Inotrem SA
Original Assignee
Inotrem SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inotrem SA filed Critical Inotrem SA
Publication of CN116490199A publication Critical patent/CN116490199A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
CN202180057069.6A 2020-06-05 2021-06-07 用于治疗患有冠状病毒感染的受试者的trem-1抑制剂 Pending CN116490199A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20305603.1 2020-06-05
EP20305603 2020-06-05
PCT/EP2021/065194 WO2021245291A1 (en) 2020-06-05 2021-06-07 Trem-1 inhibitor for use in the treatment of a subject suffering from a coronavirus infection

Publications (1)

Publication Number Publication Date
CN116490199A true CN116490199A (zh) 2023-07-25

Family

ID=71614781

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180057069.6A Pending CN116490199A (zh) 2020-06-05 2021-06-07 用于治疗患有冠状病毒感染的受试者的trem-1抑制剂

Country Status (6)

Country Link
US (1) US20230201301A1 (https=)
EP (1) EP4161551A1 (https=)
JP (1) JP2023529089A (https=)
CN (1) CN116490199A (https=)
CA (1) CA3180293A1 (https=)
WO (1) WO2021245291A1 (https=)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060084082A1 (en) 1997-03-07 2006-04-20 Human Genome Sciences, Inc. 186 human secreted proteins
US8981061B2 (en) 2001-03-20 2015-03-17 Novo Nordisk A/S Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
LT2555789T (lt) * 2010-04-08 2020-09-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Inhibuojantys peptidai, kilę iš trem tipo transkripto 1 (tlt-1), ir jų naudojimas
US9550830B2 (en) 2012-02-15 2017-01-24 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
JP6411218B2 (ja) 2012-02-15 2018-10-24 ノヴォ ノルディスク アー／エス 骨髄細胞で発現されるトリガー受容体１（ｔｒｅｍ−１）に結合し、それを遮断する抗体
AU2013311606B2 (en) * 2012-09-07 2017-10-05 Inserm (Institut National De La Sante Et De La Recherche Medicale) Inhibiting peptides derived from triggering receptor expressed on myeloid cells-1 (TREM-1) Trem-Like Transcript 1 (TLT-1) and uses thereof
US10765679B2 (en) * 2015-07-04 2020-09-08 Emory University Use of TREM-1 inhibitors for treatment, elimination and eradication of HIV-1 infection
US20210364532A1 (en) * 2018-09-28 2021-11-25 Inotrem Use of soluble trem-1 levels for identifying subjects susceptible to respond to an anti-inflammatory therapy

Also Published As

Publication number Publication date
CA3180293A1 (en) 2021-12-09
EP4161551A1 (en) 2023-04-12
US20230201301A1 (en) 2023-06-29
JP2023529089A (ja) 2023-07-07
WO2021245291A1 (en) 2021-12-09

Similar Documents

Publication Publication Date Title
AU2007337996B2 (en) Soluble urokinase plasminogen activator receptor (suPAR) as marker for diseases
US12364733B1 (en) Method for treating septic shock
CN116490199A (zh) 用于治疗患有冠状病毒感染的受试者的trem-1抑制剂
EP3342861B1 (en) Specifically purified anti-presepsin antibody
EP3701268B1 (en) Delta-like ligand 1 for diagnosing severe infections
US20250145667A1 (en) Peptide
CN102458446B (zh) 用于治疗慢性阻塞性肺病和哮喘的组合物和方法
US20230273208A1 (en) Soluble trem-1 as a marker of severity or complications for a subject suffering from a coronavirus infection
JP2024519321A (ja) 重篤患者におけるコルチコステロイドの療法層別化のための成熟アドレノメデュリン
JP2023528455A (ja) Ｉｌ－１８に対する抗体を伴う方法および処置
AU2013200398B2 (en) Soluble Urokinase Plasminogen Activator Receptor (suPAR) as Marker for Diseases
CN116507915A (zh) 可溶性trem-1作为患有冠状病毒感染的受试者的严重程度或并发症的标志物
EP3589306B1 (en) Uromodulin for use in prevention and therapy of vascular calcification or vascular inflammation
WO2022195096A1 (en) Peptide and method for direct analysis of sars-cov-2 immune responses
Quillinan Treatment of Diffuse Cutaneous Systemic Sclerosis with Hyperimmune Caprine Serum

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination